SPIKIMM, a biotechnology company founded by Truffle Capital under license from the Institut Pasteur, announces that the clinical trials for SPK001, its monoclonal antibody against SARS-COV-2, have begun
THIS CLINICAL TRIAL HAS BEEN AWARDED NATIONAL PRIORITY RESEARCH STATUS BY THE FRENCH GOVERNMENT
